Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer

References

• Allen, T. M., Brandeis, E., Hansen, C. B., Kao, G. Y., Zalipsky, S. (1995). A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1237:99–108.
   PubMed Web of Science ®Google Scholar
• Borchardt, P., Yuan, R., Miederer, M., McDevitt, M., Scheinberg, D. (2003). Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res 63:5084.
   PubMed Web of Science ®Google Scholar
• Borley, N. (Ed.). (2005) Spleen. London: Elsevier.
   Google Scholar
• Buijs, W. C. A. M., Tibben, J. G., Boerman, O. C., Molthoff, C. F. M., Massuger, L. F. A. G., Koenders, E. B., et al. (1998). Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. Eur J Nucl Med 25:1552–1561.
   PubMedGoogle Scholar
• Campbell, R. B., Fukumura, D., Brown, E. B., Mazzola, L. M., Izumi, Y., Jain, R. K., et al. (2002). Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 62:6831–6836.
   PubMed Web of Science ®Google Scholar
• Castile, J. D., Taylor, K. M. G. (1999). Factors affecting the size distribution of liposomes produced by freeze-thaw extrusion. Int J Pharm 188:87–95.
   PubMed Web of Science ®Google Scholar
• Crippa, F., Bolis, G., Seregni, E., Gavoni, N., Scarfone, G., Ferraris, C., et al. (1995). Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer 31:686–690.
   Web of Science ®Google Scholar
• Cullis, P. R., Dekruijff, B. (1979). Lipid polymorphism and the functional role of lipids in biological membranes. Biochim Biophys Acta 559:399–420.
   PubMed Web of Science ®Google Scholar
• Delgado, G., Potkul, R., Treat, J., Lewandowski, G., Barter, J., Forst, D., et al. (1989). A phase I/II study of intraperitoneally administered doxorubicin entrapped. Am J Obs Gyn 160:812.
   PubMed Web of Science ®Google Scholar
• Devaux, P. F. (1992). Protein involvement in transmembrane lipid asymmetry. Ann Rev Biophys Biomolec Struct 21:417–439.
   PubMedGoogle Scholar
• Drummond, D. D., Meyer, O., Hong, K., Kirpotin, D. B., Papahadjopoulos, D. (1999). Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691–743.
   PubMed Web of Science ®Google Scholar
• Ellens, H., Morselt, H., Scherphof, G. (1981). In vivo fate of large unilamellar sphingomyelin-cholesterol liposomes after intraperitoneal and intravenous injection into rats. Biochim Biophys Acta 674:10–18.
   PubMed Web of Science ®Google Scholar
• Epenetos, A., Munro, A., Stewart, S., Rampling, R., Lambert, H., Mckenzie, C., et al. (1987). Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 5:1890–1899.
   PubMed Web of Science ®Google Scholar
• Heniford, B., Park, A., Walsh, R., Kercher, K., Matthews, B., Frenette, G., et al. (2001). Laparoscopic splenectomy in patients with normal-sized spleens versus splenomegaly: does size matter. Am Surg 67:854–857.
   PubMed Web of Science ®Google Scholar
• Hwang, K. J., Merriam, J. E., Beaumier, P. L., Luk, K.-F. S. (1982). Encapsulation, with high efficiency, of radioactive metal ions in liposomes. Biochim Biophys Acta 716:101–109.
   PubMed Web of Science ®Google Scholar
• Kirpotin, D. B., Park, J. W., Hong, S. K., Zalipsky, S., Li, W.-L., Carter, P., et al. (1997). Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 36:66–75.
   PubMed Web of Science ®Google Scholar
• Lasic, D. D. (1993). Liposomes from physics to applications. Amsterdam, The Netherlands: Elsevier.
   Google Scholar
• Li, C.-Y., Shan, S., Huang, Q., Braun, R. D., Lanzen, J., Hu, K., et al. (2000). Initial stages of tumor cell–induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 92:143–147.
   PubMed Web of Science ®Google Scholar
• Liu, D., Mori, A., Huang, L. (1991). Large liposomes containing ganglioside GM1 accumulate effectively in spleen. Biochim Biophys Acta 1066:159–165.
   PubMed Web of Science ®Google Scholar
• Mangala, L. S., Han, H. D., Lopez-Berestein, G., Sood, A. K. (2009). Liposomal siRNA for ovarian cancer. In: Reidhaar-Olson, C. M. R. A. J. F. (Ed.), Therapeutic applications of RNAi. Humana Press, New York, NY, USA.
   Google Scholar
• Mcintyre, J. C., Sleight, R. G. (1991). Fluorescence assay for phospholipid membrane asymmetry. Biochemistry 30:11819–11827.
   PubMed Web of Science ®Google Scholar
• Meredith, R. F., Partridge, E. E., Alvarez, R. D., Khazaeli, M. B., Plott, G., Russell, C. D., et al. (1996). Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med 37:1491–1496.
   PubMed Web of Science ®Google Scholar
• Miller, C. R., Bondurant, B., Mclean, S. D., Mcgovern, K. A., O’Brien, D. F. (1998). Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of convenntional and sterically stabilized liposomes. Biochemistry 37:12875–12883.
   PubMed Web of Science ®Google Scholar
• Mujoo, K., Maneval, D. C., Anderson, S. C., Gutterman, J. U. (1996). Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 12:1617–1623.
   PubMed Web of Science ®Google Scholar
• Namiki, Y., Takahashi, T., Ohno, T. (1998). Gene transduction for disseminated intraperitoneal tumor using cationic liposomes containing nonhistone chromatin proteins: cationic liposomal gene therapy of carcinomatosa. Gene Ther 5:240–246.
   PubMed Web of Science ®Google Scholar
• Provencher, S. W. (1982). A constrained regularization method for inverting data represented by linear algebraic or integral equations. Comput Phys Commun 27: 213–227.
   Web of Science ®Google Scholar
• Rossi, C. R., Mocellin, S., Pilati, P., Foletto, M., Quintieri, L., Palatini, P., et al. (2003). Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Surg Oncol Clin North Am 12:781–794.
   PubMedGoogle Scholar
• Sadzuka, Y., Hirota, S., Sonobe, T. (2000). Intraperitoneal administration of doxorubicin encapsulating liposomes. Toxicol Lett 116:51–59.
   PubMed Web of Science ®Google Scholar
• Sapra, P., Allen, T. M. (2003). Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 42:439–462.
   PubMed Web of Science ®Google Scholar
• Sofou, S. (2007). Surface-active liposomes for targeted cancer therapy. Nanomed 2:711–724
   PubMed Web of Science ®Google Scholar
• Sofou, S. (2008). Radionuclide carriers for targeting of cancer. Int J Nanomed 3:181–199.
   PubMed Web of Science ®Google Scholar
• Stensrud, G., Redford, K., Smistad, G., Karlsen, J. (1999). Effects of gamma irradiation on solid and lyophilised phospholipids. Rad Phys Chem 56:611–622.
   Web of Science ®Google Scholar
• Syrigos, K. N., Vile, R. G., Peters, A. M., Harrington, K. J. (2003). Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes after intraperitoneal injection. Acta Oncol 42:147–153.
   PubMed Web of Science ®Google Scholar
• Takemori, N., Hirai, K., Onodera, R., Kimura, S., Katagiri, M. (1997). Durable remission after splenectomy for Waldenstrom’s macroglobulinemia with massive splenomegaly in leukemic phase. Leuk Lymph 26:387–393.
   PubMed Web of Science ®Google Scholar
• Teraoka, I. (2002). Polymer solutions: an introduction to physical properties. New York: John Wiley & Sons.
   Google Scholar
• Verschraegen, C., Kumagai, S., Davidson, R., Feig, B., Mansfield, P., Lee, S., et al. (2003). Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato(trans-R,R-1,2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol, 129:549–555.
   PubMed Web of Science ®Google Scholar
• Zhang, J.-S., Liu, F., Huang, L. (2005). Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev 57:689–698.
   PubMed Web of Science ®Google Scholar